The Safety, Acceptability, and Feasibility of Single-Dose Rifampicin as Post-Exposure Chemoprophylaxis for Contacts of Leprosy Patients in Togo: A Mixed-Method Sequential Explanatory Study
The World Health Organization is encouraging countries to include contact screening and single-dose rifampicin administration as preventive chemotherapy for contacts of leprosy patients in their leprosy control activities. However, no study has been conducted to assess the safety of SDR-PEP and the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Tropical Medicine and Infectious Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2414-6366/9/11/276 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850227926140715008 |
|---|---|
| author | Akila Wimima Bakoubayi Falapalaki Haliba Wendpouiré Ida C. Zida-Compaore P’tanam P’kontème Bando Yao Rodion Konu Abissouwèssim Egbare Tchade Kodjo Akpadja Kamevor Alaglo Maweke Tchalim P’niwè Patchali Yaovi Djakpa Komi Amekuse Piham Gnossike Denis A. Yawovi Gadah Christa Kasang Didier Koumavi Ekouevi |
| author_facet | Akila Wimima Bakoubayi Falapalaki Haliba Wendpouiré Ida C. Zida-Compaore P’tanam P’kontème Bando Yao Rodion Konu Abissouwèssim Egbare Tchade Kodjo Akpadja Kamevor Alaglo Maweke Tchalim P’niwè Patchali Yaovi Djakpa Komi Amekuse Piham Gnossike Denis A. Yawovi Gadah Christa Kasang Didier Koumavi Ekouevi |
| author_sort | Akila Wimima Bakoubayi |
| collection | DOAJ |
| description | The World Health Organization is encouraging countries to include contact screening and single-dose rifampicin administration as preventive chemotherapy for contacts of leprosy patients in their leprosy control activities. However, no study has been conducted to assess the safety of SDR-PEP and the acceptability and feasibility of this intervention in Togo. To assess the safety of SDR-PEP, we used a cohort design, and for acceptability and feasibility, we used a mixed method, combining a quantitative study to assess the safety of SDR-PEP in a cohort of contacts from recently diagnosed leprosy patients followed by a qualitative study to identify the social, cultural, or institutional factors that would influence the adoption of single-dose rifampicin as post-exposure prophylaxis for contacts of leprosy patients in Togo. For the quantitative study, all identified index patients agreed to the disclosure of their status to their contacts and provided a list of their contacts. All the contacts found agreed to take part in the study, and an appointment was made for screening. However, some contacts were absent on the screening day for no reason. All eligible contacts agreed to take SDR and were followed up after taking the drug. No severe adverse events were reported during the follow-up. For the qualitative study, 72 interviews (66 semi-structured interviews and 6 focus groups) were carried out, and it emerged that, overall, opinions were favorable on the acceptability and feasibility of implementing single-dose rifampicin as post-exposure prophylaxis for contacts of leprosy patients in Togo. However, a number of conditions need to be considered for more effective results. |
| format | Article |
| id | doaj-art-09e2b76847f4424e83a746f999b7e2db |
| institution | OA Journals |
| issn | 2414-6366 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Tropical Medicine and Infectious Disease |
| spelling | doaj-art-09e2b76847f4424e83a746f999b7e2db2025-08-20T02:04:41ZengMDPI AGTropical Medicine and Infectious Disease2414-63662024-11-0191127610.3390/tropicalmed9110276The Safety, Acceptability, and Feasibility of Single-Dose Rifampicin as Post-Exposure Chemoprophylaxis for Contacts of Leprosy Patients in Togo: A Mixed-Method Sequential Explanatory StudyAkila Wimima Bakoubayi0Falapalaki Haliba1Wendpouiré Ida C. Zida-Compaore2P’tanam P’kontème Bando3Yao Rodion Konu4Abissouwèssim Egbare Tchade5Kodjo Akpadja6Kamevor Alaglo7Maweke Tchalim8P’niwè Patchali9Yaovi Djakpa10Komi Amekuse11Piham Gnossike12Denis A. Yawovi Gadah13Christa Kasang14Didier Koumavi Ekouevi15German Leprosy and Tuberculosis Relief Association, Lome 2271, TogoGerman Leprosy and Tuberculosis Relief Association, Lome 2271, TogoDepartment of Public Health, Faculty of Health Sciences, University of Lome, Lome 1515, TogoGerman Leprosy and Tuberculosis Relief Association, Lome 2271, TogoDepartment of Public Health, Faculty of Health Sciences, University of Lome, Lome 1515, TogoDepartment of Public Health, Faculty of Health Sciences, University of Lome, Lome 1515, TogoNational Tuberculosis Control Program, Lome 2271, TogoNational Neglected Tropical Diseases Control Program, Lome 336, TogoNational Neglected Tropical Diseases Control Program, Lome 336, TogoNational Neglected Tropical Diseases Control Program, Lome 336, TogoGerman Leprosy and Tuberculosis Relief Association, Lome 2271, TogoGerman Leprosy and Tuberculosis Relief Association, Lome 2271, TogoNational Neglected Tropical Diseases Control Program, Lome 336, TogoGerman Leprosy and Tuberculosis Relief Association, Lome 2271, TogoGerman Leprosy and Tuberculosis Relief Association, 97080 Würzburg, GermanyDepartment of Public Health, Faculty of Health Sciences, University of Lome, Lome 1515, TogoThe World Health Organization is encouraging countries to include contact screening and single-dose rifampicin administration as preventive chemotherapy for contacts of leprosy patients in their leprosy control activities. However, no study has been conducted to assess the safety of SDR-PEP and the acceptability and feasibility of this intervention in Togo. To assess the safety of SDR-PEP, we used a cohort design, and for acceptability and feasibility, we used a mixed method, combining a quantitative study to assess the safety of SDR-PEP in a cohort of contacts from recently diagnosed leprosy patients followed by a qualitative study to identify the social, cultural, or institutional factors that would influence the adoption of single-dose rifampicin as post-exposure prophylaxis for contacts of leprosy patients in Togo. For the quantitative study, all identified index patients agreed to the disclosure of their status to their contacts and provided a list of their contacts. All the contacts found agreed to take part in the study, and an appointment was made for screening. However, some contacts were absent on the screening day for no reason. All eligible contacts agreed to take SDR and were followed up after taking the drug. No severe adverse events were reported during the follow-up. For the qualitative study, 72 interviews (66 semi-structured interviews and 6 focus groups) were carried out, and it emerged that, overall, opinions were favorable on the acceptability and feasibility of implementing single-dose rifampicin as post-exposure prophylaxis for contacts of leprosy patients in Togo. However, a number of conditions need to be considered for more effective results.https://www.mdpi.com/2414-6366/9/11/276leprosysingle-dose rifampicinpost-exposure prophylaxisacceptabilityfeasibilityTogo |
| spellingShingle | Akila Wimima Bakoubayi Falapalaki Haliba Wendpouiré Ida C. Zida-Compaore P’tanam P’kontème Bando Yao Rodion Konu Abissouwèssim Egbare Tchade Kodjo Akpadja Kamevor Alaglo Maweke Tchalim P’niwè Patchali Yaovi Djakpa Komi Amekuse Piham Gnossike Denis A. Yawovi Gadah Christa Kasang Didier Koumavi Ekouevi The Safety, Acceptability, and Feasibility of Single-Dose Rifampicin as Post-Exposure Chemoprophylaxis for Contacts of Leprosy Patients in Togo: A Mixed-Method Sequential Explanatory Study Tropical Medicine and Infectious Disease leprosy single-dose rifampicin post-exposure prophylaxis acceptability feasibility Togo |
| title | The Safety, Acceptability, and Feasibility of Single-Dose Rifampicin as Post-Exposure Chemoprophylaxis for Contacts of Leprosy Patients in Togo: A Mixed-Method Sequential Explanatory Study |
| title_full | The Safety, Acceptability, and Feasibility of Single-Dose Rifampicin as Post-Exposure Chemoprophylaxis for Contacts of Leprosy Patients in Togo: A Mixed-Method Sequential Explanatory Study |
| title_fullStr | The Safety, Acceptability, and Feasibility of Single-Dose Rifampicin as Post-Exposure Chemoprophylaxis for Contacts of Leprosy Patients in Togo: A Mixed-Method Sequential Explanatory Study |
| title_full_unstemmed | The Safety, Acceptability, and Feasibility of Single-Dose Rifampicin as Post-Exposure Chemoprophylaxis for Contacts of Leprosy Patients in Togo: A Mixed-Method Sequential Explanatory Study |
| title_short | The Safety, Acceptability, and Feasibility of Single-Dose Rifampicin as Post-Exposure Chemoprophylaxis for Contacts of Leprosy Patients in Togo: A Mixed-Method Sequential Explanatory Study |
| title_sort | safety acceptability and feasibility of single dose rifampicin as post exposure chemoprophylaxis for contacts of leprosy patients in togo a mixed method sequential explanatory study |
| topic | leprosy single-dose rifampicin post-exposure prophylaxis acceptability feasibility Togo |
| url | https://www.mdpi.com/2414-6366/9/11/276 |
| work_keys_str_mv | AT akilawimimabakoubayi thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT falapalakihaliba thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT wendpouireidaczidacompaore thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT ptanampkontemebando thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT yaorodionkonu thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT abissouwessimegbaretchade thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT kodjoakpadja thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT kamevoralaglo thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT maweketchalim thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT pniwepatchali thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT yaovidjakpa thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT komiamekuse thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT pihamgnossike thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT denisayawovigadah thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT christakasang thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT didierkoumaviekouevi thesafetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT akilawimimabakoubayi safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT falapalakihaliba safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT wendpouireidaczidacompaore safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT ptanampkontemebando safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT yaorodionkonu safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT abissouwessimegbaretchade safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT kodjoakpadja safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT kamevoralaglo safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT maweketchalim safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT pniwepatchali safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT yaovidjakpa safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT komiamekuse safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT pihamgnossike safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT denisayawovigadah safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT christakasang safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy AT didierkoumaviekouevi safetyacceptabilityandfeasibilityofsingledoserifampicinaspostexposurechemoprophylaxisforcontactsofleprosypatientsintogoamixedmethodsequentialexplanatorystudy |